目的 探討保利爾膠囊聯(lián)合非諾貝特治療高脂血癥的臨床療效。方法 選取2021年5月—2023年5月中國(guó)中醫(yī)科學(xué)院廣安門(mén)醫(yī)院收治的98例高血脂癥患者，按照隨機(jī)數(shù)字法將患者分為對(duì)照組（49例）和治療組（49例）。對(duì)照組隨餐口服非諾貝特膠囊，0.2 g/次，1次/d。在對(duì)照組的基礎(chǔ)上，治療組口服保利爾膠囊，5粒/次，3次/d。兩組患者治療15 d。觀(guān)察兩組患者臨床療效，比較治療前后兩組患者癥狀改善時(shí)間，血清總膽固醇、瘦素、血沉、脂聯(lián)素、白細(xì)胞介素-6（IL-6）、IL-1β、細(xì)胞間黏附分子-1（ICAM-1）和超氧化物歧化酶（SOD）水平，及不良反應(yīng)情況。結(jié)果 治療后，治療組臨床總有效率（97.96%）明顯高于對(duì)照組（81.63%，P＜0.05）。治療后，治療組癥狀改善時(shí)間均明顯早于對(duì)照組（P＜0.05）。治療后，兩組脂聯(lián)素和SOD明顯高于治療前，而總膽固醇、瘦素、血沉、IL-6、IL-1β、ICAM-1水平均明顯低于治療前（P＜0.05），且治療組這些血清因子水平明顯好于對(duì)照組（P＜0.05）。治療后，治療組不良反應(yīng)發(fā)生率（6.22%）明顯低于對(duì)照組發(fā)生率（16.33%，P＜0.05）。結(jié)論 非諾貝特與保利爾膠囊協(xié)同治療效果確切，對(duì)臨床癥狀可以有效改善，能使高血脂有效調(diào)節(jié)，并減弱機(jī)體炎性反應(yīng)狀態(tài)。

Objective To explore the clinical effect of Baolile Capsules combined with fenofibrate in treatment of hyperlipidemia. Methods Patients (98 cases) with hyperlipidemia admitted to Guang’anmen Hospital of China Academy of Chinese Medical Sciences from May 2021 to May 2023 were selected and divided into control group (49 cases) and treatment group (49 cases) according to random number method. Patients in the control group were po administered with Fenofibrate Capsules, 0.2 g/time, once daily. Patients in the treatment group were po administered with Baolier Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 15 d. After treatment, the clinical effect was evaluated, and the symptom relief times, the levels of total cholesterol, leptin, erythrocyte sedimentation rate, adiponectin, IL-6, IL-1β, ICAM-1, and SOD, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (97.96%) was significantly higher than that of the control group (81.63%, P < 0.05). After treatment, the time of symptom improvement in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of adiponectin and SOD in two groups were significantly higher than those before treatment, while the levels of total cholesterol, leptin, ESR, IL-6, IL-1β, and ICAM-1 were significantly lower than those before treatment (P < 0.05), and the levels of these serum factors in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the incidence of adverse events in the treatment group (6.22%) was significantly lower than that in the control group (16.33%, P < 0.05). Conclusion Baolier Capsules combined with fenofibrate are effective in the treatment of hyperlipidemia, which can effectively improve the clinical symptoms, regulate hyperlipidemia and weaken the inflammatory state.

R972